Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Science Board noms

This article was originally published in The Tan Sheet

Executive Summary

FDA requests nominations for membership on its Science Board, which advises the commissioner on technical issues, regulatory science and research agendas, according to a Sept. 5 Federal Register notice. Send nominations of individuals knowledgeable in the fields of food safety, nutrition, pharmacology, nanotechnology and other scientific disciplines to FDA at by Oct. 6. In May, FDA Commissioner Andrew von Eschenbach said he intends to expand the board from 11 to 21 members and double its annual meetings from two to four in response to a board report pointing to the agency's deficiencies in expertise and technology (2"The Tan Sheet" June 30, 2008, p. 12)

You may also be interested in...

FDA Expects Greater Scientific Impact With Larger Advisory Board

FDA Commissioner Andrew von Eschenbach is attempting to increase the impact of the agency's Science Board Advisory Committee by doubling the number of members and meetings

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts